ArticleAnti-cancer agents in medicinal chemistry2025
Article in Anti-cancer agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCisplatin (CIS) is a standard chemotherapeutic drug currently used for various cancer treatments. Due to its chemo-resistance and toxic effects, a new combinatorial approach was preferred. Oleanolic acid is one such pentacyclic terpenoid compound that tends to have various anti-cancer properties against a wide range of human carcinoma models. Yet, the final mechanisms of individual and Combinational Treatment of OA and CIS on pancreatic carcinoma persist indescribable.
objectiveThe Current study analyses the METHODS AND MATERIAL: The preliminary screening of the anti-cancer effect of OA and CIS was evaluated meticulously using docking score with Auto-Dock. For further
resultsMolecular docking analysis suggests that OA and CIS possess a strong binding affinity for hydrogen bond interaction with the highest fitness score for various anti-cancer genes, leading to the drug's significant apoptotic and anti-angiogenic effects. Further preliminary analysis reports of UV spectra and GC-MS data suggested that the OA compound tends to exhibit a peak at 235-288 nm with a GC retention time of 15.45 min with m/z 240 and m/z 280 ratios. The output of
conclusionIn conclusion, the present study indicates that the co-treatment of OA with CIS in pancreatic cancer cells exerts strong interaction with synergistic effects on cell growth inhibition, apoptosis induction, and angiogenesis genes through regulating signal-target proteins applicable for pancreatic cancer.
Indexed as
Identifiers
39931858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.